Hong JG, Yan LJ, Li X, Yao SY, Su P, Li HC, Ding ZN, Wang DX, Dong ZR, Li T. Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2022; 28(6): 689-692 [PMID: 35317426 DOI: 10.3748/wjg.v28.i6.689]
Corresponding Author of This Article
Tao Li, MD, Chief Doctor, Department of General Surgery, Qilu Hospital of Shandong University, No. 107 West Wenhua Road, Jinan 250012, Shandong Province, China. litao7709@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 14, 2022; 28(6): 689-692 Published online Feb 14, 2022. doi: 10.3748/wjg.v28.i6.689
Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease
Jian-Guo Hong, Lun-Jie Yan, Xian Li, Sheng-Yu Yao, Peng Su, Hai-Chao Li, Zi-Niu Ding, Dong-Xu Wang, Zhao-Ru Dong, Tao Li
Jian-Guo Hong, Lun-Jie Yan, Xian Li, Sheng-Yu Yao, Hai-Chao Li, Zi-Niu Ding, Dong-Xu Wang, Zhao-Ru Dong, Tao Li, Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Peng Su, Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Author contributions: Li X and Yao SY designed and performed the research; Yan LJ, Li HC and Ding ZN analyzed the data; Li T and Hong JG wrote the letter; Yan LJ, Su P, Wang DX and Dong ZR revised the letter; Hong JG, Yan LJ, Li X, Yao SY, and Su P contributed equally to this article.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Li, MD, Chief Doctor, Department of General Surgery, Qilu Hospital of Shandong University, No. 107 West Wenhua Road, Jinan 250012, Shandong Province, China. litao7709@126.com
Received: October 5, 2021 Peer-review started: October 5, 2021 First decision: November 15, 2021 Revised: December 5, 2021 Accepted: January 17, 2022 Article in press: January 17, 2022 Published online: February 14, 2022 Processing time: 126 Days and 14.9 Hours
Abstract
To evaluate and predict liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), several non-invasive scoring systems were built and widely used in the progress of diagnosis and treatment, which showed great diagnostic efficiency, such as aspartate aminotransferase to platelet ratio index, fibrosis-4 index, body mass index, aspartate aminotransferase to alanine aminotransferase ratio, diabetes score and NAFLD fibrosis score. Since the new concept of metabolic associated fatty liver disease (MAFLD) was proposed, the clinical application value of the non-invasive scoring systems mentioned above has not been assessed in MAFLD. The evaluation of the diagnostic performance of these non-invasive scoring systems will provide references for clinicians in the diagnosis of MAFLD.
Core Tip: The concept of metabolic associated fatty liver disease (MAFLD) was proposed in 2020. Unlike the concept of nonalcoholic fatty liver disease, the exclusion of chronic liver disease was not required in the establishment of diagnosis of MAFLD, but the presence of metabolic associated disease or dysfunction is required. The clinical prediction values and the optimal cutoff values of non-invasive fibrosis scores remain unknown. We read the recent article entitled “Validation of Conventional Non-invasive Fibrosis Scoring Systems in Patients with Metabolic Associated Fatty Liver Disease” with great interest. We would like to share our opinions and criticisms about this valuable work.
